Clinical trials: HIV Lipodystrophy Syndrome
HIV, Metabolic Diseases
Study of Lifestyle Modification in HIV Lipodystrophy
This study is designed to determine the effects of an intensive lifestyle modification program in patients with HIV and Metabolic Syndrome.
- Trial name
- NCT00111358
- Testing
- Lifestyle Modification, No lifestyle modification
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, Lipodystrophy
Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities
The purpose of this study is to see whether metformin alone, rosiglitazone alone, or metformin and rosiglitazone together will lower insulin levels in the blood and decrease fat in the abdomen or other parts of the body.
- Conditions
- HIV Infections, Lipodystrophy, Hyperinsulinemia
- Trial name
- NCT00015691
- Testing
- Metformin hydrochloride, Rosiglitazone maleate
- Where
- 34 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular…
- Trial name
- NCT00192660
- Testing
- Lamivudine, Stavudine, Didanosine
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV, AIDS
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
The main aim of the study is to investigate the combined effects of using anabolic steroids and protease inhibitors on fat metabolism and body composition of People Living with HIV/AIDS.
- Conditions
- HIV, AIDS, Lipodystrophy, Hyperlipidemia
- Trial name
- NCT00202241
- Testing
- testosterone injection
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Queen's University
HIV Infections, Lipid Metabolism
Pravastatin for Hyperlipidaemia in HIV.
This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol.
- Conditions
- HIV Infections, Lipid Metabolism, Glucose Metabolism, Metabolic Abnormality
- Trial name
- NCT00227500
- Testing
- Pravastatin
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Kirby Institute
HIV Infection
A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine
The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz…
- Trial name
- LYNX (NCT01159743)
- Where
- 26 sites in Spain
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV-Associated Lipodystrophy, HIV Infections
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to…
- Trial name
- NCT00126308
- Testing
- poly-L-lactic acid
- Where
- 18 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
HIV Infections, HIV-Associated Lipodystrophy Syndrome
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
The purpose of this study is to assess the prevalence of metabolic and physical abnormalities in HIV infected (via mother-to-child transmission) and uninfected children and youth.
- Conditions
- HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy
- Trial name
- NCT00069004
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
The purpose of this study is to find out whether certain anti-HIV drugs (efavirenz [EFV] and nelfinavir [NFV]) affect the amount of certain fat-lowering drugs (atorvastatin, pravastatin, and simvastatin) in the blood.
- Conditions
- HIV Infections, HIV Seronegativity, Lipodystrophy
- Trial name
- NCT00017758
- Testing
- Pravastatin sodium, Simvastatin, Atorvastatin calcium
- Where
- 10 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, Lipodystrophy
Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects
Magnetic resonance spectroscopy (MRS) is commonly applied in medicine with 1H proton or 31-phosphorus spectra. The proton MRS is often used in evaluating the central nervous system and 31P MRS is used in muscular diseases or…
- Trial name
- NCT00172315
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
HIV Infections, Lipodystrophy-Syndrome
Role of the Autonomic Nervous System in HIV-Lipodystrophy
The study aims to characterise the influence of the autonomic nervous system activity on the development of the lipodystrophy syndrome in HIV-infected patients by measuring heart rate variability and various metabolic pathways in…
- Trial name
- NCT00149097
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Hannover Medical School
HIV Infections
HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
This study is being done to better understand why people with HIV who have taken drugs for HIV begin to show abnormal changes in fat loss or fat gain in their bodies. This condition is called lipodystrophy.
- Trial name
- HAL (NCT01023620)
- Testing
- Pioglitazone, Observation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
The purpose of this study is to look at the effects of different anti-HIV drug combinations on body fat changes in HIV-positive patients who have never received anti-HIV therapy before.
- Trial name
- NCT00005106
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaxo Wellcome
HIV Infections, Lipodystrophy
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
HIV infection is a major global health problem. Survival and quality of life for HIV subjects has tremendously improved with the advent of a class of antivirals called protease inhibitors and the utilization of highly active…
- Trial name
- NCT00006190
- Testing
- Nelfinavir mesylate, Stavudine, Lamivudine
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Human Immunodeficiency Virus, Facial Lipoatrophy
Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid
Evaluate and record any changes in the Quality of Life and psychological state of the affected study group following treatment with Bio-Alcamid.
- Trial name
- NCT00333684
- Testing
- BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
Lipodystrophy Syndrome, HIV, Sarcopenia
Detraining in People Living With HIV/AIDS
The goal of this study was to evaluate the effect of detraining in the components of physical aptitude of people living with HIV/Aids (PVHA).
- Trial name
- PVHA (NCT03075332)
- Testing
- combined training
- Where
- 2 sites in Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
HIV Infections, Lipodystrophy
Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults
The purpose of this study is to collect data on the body's breakdown of sugar and fat in HIV infected adults. Data from this study will make clearer the roles of HIV infection and anti-HIV drugs in the development of diabetes…
- Conditions
- HIV Infections, Lipodystrophy, Diabetes, Hyperlipidemia
- Trial name
- NCT00331448
- Volunteers
- 1,483 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Lipodystrophy
Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs
The purpose of this study is to learn how changes in body build affect the lives of people taking anti-HIV medications. By learning this, a set of questions can be created to help understand how changes in body build and image…
- Trial name
- NCT00006290
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with…
- Trial name
- NCT00122668
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic